Did Garin and Bujadoux Actually Report a Case of Lyme Radiculoneuritis?

Wormser, Gary P.; Wormser, Vanessa

doi:10.1093/ofid/ofw085

Cited by 4 publications

(2 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…He was the first to describe this expanding diseasedefining skin rash (4), which was subsequently referred to as erythema chronicum migrans, This descriptor was eventually shortened to erythema migrans near the end of the 20th century (2,3). In terms of systemic disease, the first known case of extracutaneous complications possibly due to Lyme disease was reported 100 years ago by the French physicians Garin and Bujadoux (5), although further analyses (6,7) have cast some doubt that some of the evidence presented in this early report as being characteristic of this condition (aka Lyme borreliosis). It wasn't, however, until the early 1980s, that research done by Dr. Willy Burgdorfer identified the spirochetal bacterium Borrelia burgdorferi as the etiologic agent (8).…”

Section: Historical Background and Epidemiology Leading To Vaccine De...mentioning

confidence: 99%

The major epidemiologic, microbiologic, immunologic, and clinical aspects of Lyme disease that form the basis for a newly developed vaccine that may become available soon for human use

Pavia,

Saggio,

Plummer

2024

Front. Immunol.

View full text Add to dashboard Cite

Working together, two major pharmaceutical companies have developed a Lyme disease vaccine consisting of recombinant-derived outer surface protein A (OspA) of the etiologic agent Borrelia burgdorferi. Multiple clinical trials have shown the vaccine to have good safety and efficacy results, and it is hoped that it would become available for human use at least by the year 2025 after receiving approval from the U.S. Food and Drug Administration. There are still challenges left to ensure that the vaccine has, at most, minimal side effects. Also, because the previously developed Lyme disease vaccine was discontinued in 2002 after four years of distribution, due in part, for frivolous reasons having little or no scientific basis, that even led to legal entanglements involving the vaccine manufacturer and some of the medical personnel overseeing the clinical trials, there will be concerns that this newly developed one could be subject again to some of the same unnecessary scrutiny rendering its implementation suboptimal. Initially this review will focus on the key epidemiological, microbiologic, immunologic and clinical aspects of Lyme disease that provide the foundation for developing this type of vaccine that could have a serious impact on the prevalence of this and even certain other tick-transmitted infections.

show abstract

Section: Historical Background and Epidemiology Leading To Vaccine De...mentioning

confidence: 99%

The major epidemiologic, microbiologic, immunologic, and clinical aspects of Lyme disease that form the basis for a newly developed vaccine that may become available soon for human use

Pavia,

Saggio,

Plummer

2024

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…These symptoms include erythema migrans, nonspecific constitutional symptoms, arthritis, carditis, and various neurologic manifestations termed as neuroborreliosis [4]. The first case of neurologic Lyme borreliosis was reported by Garin and Bujadoux in 1992 when they described a patient in France with meningoradiculitis after an erythema migrans following a tick bite [5]. Neuroborreliosis is only seen in 10-15% of LD cases, and it most commonly presents as painful radiculitis, cranial palsy (mostly facial palsy), and headache [6].…”

Section: Introductionmentioning

confidence: 99%

Neuroborreliosis Presenting as Guillain-Barré Syndrome

Farr,

Bittar

2023

Cureus

View full text Add to dashboard Cite

Lyme disease (LD) is the most common vector-borne disease in the United States. The early localized disease presents with erythema migrans and nonspecific constitutional symptoms. A neurological manifestation of LD (neuroborreliosis) is only seen in 10-15% of LD cases, and it typically presents as cranial neuritis or painful radiculitis. We report a case of a 33-year-old male who presented with progressive ascending bilateral lower extremities weakness with paresthesia in hands and feet following an upper respiratory tract infection and an abdominal rash. Cerebrospinal fluid (CSF) analysis revealed albuminocytologic dissociation. An electrodiagnostic study showed prolonged distal motor latency, conduction block, and absent F-wave response. Magnetic resonance imaging of the lumbar spine revealed enhancement of the cauda equina nerve roots. After a lack of improvement with intravenous immunoglobulin for presumed Guillain-Barré syndrome (GBS), Lyme serologies were sent and showed positive Lyme antibodies in serum and CSF as well as positive western blot IgM followed by IgG seroconversion a week later. The patient was started on IV ceftriaxone and doxycycline for four weeks with significant improvement in his symptoms. This is a rare case of LD presenting as GBS. Lyme can have diverse neurologic manifestations and should be considered in the differential diagnosis of GBS in the appropriate settings.

show abstract

Immunologic detection of Lyme disease and the related borrelioses

Pavia

2020

Methods in Microbiology

View full text Add to dashboard Cite

Did Garin and Bujadoux Actually Report a Case of Lyme Radiculoneuritis?

Abstract: Although a 1922 report by Garin and Bujadoux is widely regarded as describing the first case of neurologic Lyme borreliosis, the many highly atypical features raises the question of whether the paper deserves the historic recognition that it has received.

Cited by 4 publications

References 32 publications

The major epidemiologic, microbiologic, immunologic, and clinical aspects of Lyme disease that form the basis for a newly developed vaccine that may become available soon for human use

The major epidemiologic, microbiologic, immunologic, and clinical aspects of Lyme disease that form the basis for a newly developed vaccine that may become available soon for human use

Neuroborreliosis Presenting as Guillain-Barré Syndrome

Immunologic detection of Lyme disease and the related borrelioses

Contact Info

Product

Resources

About